XML 78 R15.htm IDEA: XBRL DOCUMENT v3.25.3
Restructuring Plans
9 Months Ended
Sep. 30, 2025
Restructuring and Related Activities [Abstract]  
Restructuring Plans Restructuring Plans
AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. As of September 30, 2025 and 2024, no such plans were individually significant. Restructuring charges were $36 million for the three months and $189 million for the nine months ended September 30, 2025 and $30 million for the three months and $94 million for the nine months ended September 30, 2024. These charges are recognized in cost of products sold, R&D expense and SG&A expense in the condensed consolidated statements of earnings based on the classification of the affected employees or the related operations.
The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2025:
(in millions)
Accrued balance as of December 31, 2024$236 
Restructuring charges77 
Payments and other adjustments(73)
Accrued balance as of September 30, 2025$240